PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy

被引:275
|
作者
Mayo, LD
Dixon, JE
Durden, DL
Tonks, NK
Donner, DB
机构
[1] Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA
[2] Walther Canc Inst, Indianapolis, IN 46202 USA
[3] Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA
[4] Indiana Univ, Sch Med, Sect Hematol & Oncol, Indianapolis, IN 46202 USA
[5] Indiana Univ, Sch Med, Herman B Wells Ctr Pediatr Res, Indianapolis, IN 46202 USA
[6] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA
关键词
D O I
10.1074/jbc.M108302200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The PTEN tumor suppressor protein inhibits phosphatidylinositol. 3-kinase (PI3K)/Akt signaling that promotes translocation of Mdm2 into the nucleus. When restricted to the cytoplasm, Mdm2 is degraded. The ability of PTEN to inhibit the nuclear entry of Mdm2 increases the cellular content and transactivation of the p53 tumor suppressor protein. Retroviral transduction of PTEN into U87MG (PTEN null) glioblastoma cells increases p53 activity and expression of p53 target genes and induces cell cycle arrest. U87MG/PTEN glioblastoma cells are more sensitive than U87MG/PTEN null cells to death induced by etoposide, a chemotherapeutic agent that induces DNA damage. Previously, tumor suppressor proteins have been supposed to act individually to suppress cancers. Our results establish a direct connection between the activities of two major tumor suppressors and show that they act together to respond to stresses and malignancies. PTEN protects p53 from survival signals, permitting p53 to function as a guardian of the genome. By virtue of its capacity to protect p53, PTEN can sensitize tumor cells to chemotherapy that relies on p53 activity. p53 induces PTEN gene expression, and here it is shown that PTEN protects p53, indicating that a positive feedback loop may amplify the cellular response to stress, damage, and cancer.
引用
收藏
页码:5484 / 5489
页数:6
相关论文
共 50 条
  • [1] PTEN Sensitizes MDM2-overexpressing acute lymphoblastic leukemia cells to chemotherapy by inhibiting MDM2 binding to p53
    Zhou, MX
    Gu, LB
    Zhu, YR
    Woods, WG
    Findley, HW
    [J]. BLOOD, 2002, 100 (11) : 206B - 206B
  • [2] p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53
    Christine Wasylyk
    Roberto Salvi
    Manuela Argentini
    Christine Dureuil
    Isabelle Delumeau
    Joseph Abecassis
    Laurent Debussche
    Bohdan Wasylyk
    [J]. Oncogene, 1999, 18 : 1921 - 1934
  • [3] p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53
    Wasylyk, C
    Salvi, R
    Argentini, M
    Dureuil, C
    Delumeau, I
    Abecassis, J
    Debussche, L
    Wasylyk, B
    [J]. ONCOGENE, 1999, 18 (11) : 1921 - 1934
  • [4] The p53 and Mdm2 families in cancer
    Michael, D
    Oren, M
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 2002, 12 (01) : 53 - 59
  • [5] MDM2 liberates from p53
    Capoulade, C
    Wiels, J
    [J]. M S-MEDECINE SCIENCES, 1999, 15 (04): : 524 - 527
  • [6] p53 and Mdm2: not all cells are equal
    Coates, P. J.
    [J]. JOURNAL OF PATHOLOGY, 2007, 213 (04): : 357 - 359
  • [7] P53 Mdm2 Inhibitors
    Khoury, Kareem
    Doemling, Alex
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (30) : 4668 - 4678
  • [8] MDM2与p53
    金晶
    刘耕陶
    [J]. 癌症, 2001, (06) : 663 - 666
  • [9] MDM2 and BCL-2: to p53 or not to p53?
    Wang, Eunice S.
    [J]. BLOOD, 2023, 141 (11) : 1237 - 1238
  • [10] Binding of an inhibitor of the p53/MDM2 interaction to MDM2
    Duncan, SJ
    Cooper, MA
    Williams, DH
    [J]. CHEMICAL COMMUNICATIONS, 2003, (03) : 316 - 317